Cessatech A/S, a promising player in the pharmaceutical industry, has made a strategic move to bolster its financial standing by announcing a directed share issue. The decision, revealed on May 28, 2025, involves the issuance of 1,163,123 new shares at a subscription price of DKK 12.72 per share, raising approximately DKK 14.8 million before transaction costs.

The company's board of directors opted for a directed issue over a rights issue, citing the current market conditions and the need for a swift and cost-effective capital increase. This decision aligns with Cessatech's strategic objectives, particularly as it prepares for the commercial launch of CT001 in the U.S. under the FDA early access program.

Cessatech has achieved several significant milestones in 2025, including a positive MDR assessment for CT001 and the successful completion of the 0202 study, which met all primary endpoints. The directed issue is expected to enhance Cessatech's financial flexibility, allowing for additional investments in U.S. commercial activities in partnership with Ventis Pharma.

Despite the dilution of approximately 6.3% for existing shareholders, the board believes that the benefits of the directed issue outweigh the potential downsides. The accelerated bookbuilding process led by Sedermera Corporate Finance AB ensured a market-driven subscription price, minimizing the impact on existing shareholders.

Investors should consider the potential growth opportunities presented by the U.S. launch of CT001. While the directed issue may cause short-term dilution, the long-term prospects for Cessatech appear promising. Given the strategic execution and the anticipated U.S. market entry, the recommendation is to hold the stock for now, awaiting further developments and potential value appreciation.